Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC152949 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 17746 |
0.1-0.2 | 11422 |
0.2-0.3 | 1186 |
0.3-0.4 | 422 |
0.4-0.5 | 76 |
0.5-0.6 | 9 |
0.6-0.7 | 14 |
0.7-0.8 | 9 |
0.8-0.85 | 0 |
0.85-0.9 | 2 |
0.9-0.95 | 3 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC152949 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 1252 |
0.1-0.2 | 6471 |
0.2-0.3 | 991 |
0.3-0.4 | 313 |
0.4-0.5 | 82 |
0.5-0.6 | 38 |
0.6-0.7 | 5 |
0.7-0.8 | 6 |
0.8-0.85 | 2 |
0.85-0.9 | 0 |
0.9-0.95 | 1 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9286 |
High Similarity |
NPD401 |
Approved |
0.8333 |
Intermediate Similarity |
NPD1156 |
Clinical (unspecified phase) |
0.8065 |
Intermediate Similarity |
NPD2276 |
Clinical (unspecified phase) |
0.7931 |
Intermediate Similarity |
NPD9465 |
Approved |
0.7586 |
Intermediate Similarity |
NPD9063 |
Approved |
0.7586 |
Intermediate Similarity |
NPD9064 |
Approved |
0.7429 |
Intermediate Similarity |
NPD2707 |
Clinical (unspecified phase) |
0.7308 |
Intermediate Similarity |
NPD8560 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD2273 |
Clinical (unspecified phase) |
0.6774 |
Remote Similarity |
NPD8544 |
Approved |
0.6579 |
Remote Similarity |
NPD1463 |
Clinical (unspecified phase) |
0.641 |
Remote Similarity |
NPD9227 |
Discontinued |
0.625 |
Remote Similarity |
NPD9458 |
Approved |
0.6216 |
Remote Similarity |
NPD9059 |
Approved |
0.5926 |
Remote Similarity |
NPD7383 |
Phase 3 |
0.5854 |
Remote Similarity |
NPD718 |
Approved |
0.5854 |
Remote Similarity |
NPD390 |
Approved |
0.5814 |
Remote Similarity |
NPD1154 |
Phase 3 |
0.5778 |
Remote Similarity |
NPD396 |
Approved |
0.5778 |
Remote Similarity |
NPD395 |
Approved |
0.575 |
Remote Similarity |
NPD8822 |
Approved |
0.5714 |
Remote Similarity |
NPD5384 |
Approved |
0.5714 |
Remote Similarity |
NPD5385 |
Approved |
0.5714 |
Remote Similarity |
NPD2274 |
Approved |
0.5714 |
Remote Similarity |
NPD2275 |
Approved |
0.5682 |
Remote Similarity |
NPD398 |
Approved |
0.5682 |
Remote Similarity |
NPD399 |
Approved |
0.5682 |
Remote Similarity |
NPD400 |
Approved |
0.5676 |
Remote Similarity |
NPD1832 |
Approved |
0.5676 |
Remote Similarity |
NPD1833 |
Approved |
0.5625
|
Remote Similarity |
NPD8791 |
Clinical (unspecified phase) |